Scholarlink

<p>The study evaluated the short-term effectiveness and tolerability of vigabatrin therapy in children with infantile epileptic spasms syndrome (IESS). Children with IESS were enrolled within two weeks of initiation of vigabatrin and prospectively followed up to 12 wk for complete cessation of epileptic spasms (ES) and occurrence of adverse events. Of 107 children studied, there was a preponderance of structural etiology (82.2%) and male sex (69.2%). Thirty percent of children achieved a complete cessation of ES for at least four weeks at a median dose of 95&#xa0;mg/kg/d (Q1, Q3: 50, 125). Among responders, 84.4% achieved cessation of ES within two weeks of initiation of therapy. 12.5% of children had a relapse over a 12-wk follow-up. Thirteen percent of children had adverse events, drowsiness being the most common (9.3%). The present study demonstrated modest short-term clinical effectiveness and tolerability of vigabatrin therapy in children with hormonal-therapy-resistant IESS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Short-Term Effectiveness and Tolerability of Vigabatrin Therapy in Infantile Epileptic Spasms Syndrome

  • 期刊论文

  • 发表日期：

    2025年1月8日

查看全文
  • Shikha Sharma,
  • Pooja Dhir,
  • Sandeep Negi,
  • Pankaj Pal,
  • Renu Suthar,
  • Arushi Saini,
  • Bikash Medhi,
  • Naveen Sankhyan,
  • Jitendra K. Sahu

摘要

The study evaluated the short-term effectiveness and tolerability of vigabatrin therapy in children with infantile epileptic spasms syndrome (IESS). Children with IESS were enrolled within two weeks of initiation of vigabatrin and prospectively followed up to 12 wk for complete cessation of epileptic spasms (ES) and occurrence of adverse events. Of 107 children studied, there was a preponderance of structural etiology (82.2%) and male sex (69.2%). Thirty percent of children achieved a complete cessation of ES for at least four weeks at a median dose of 95 mg/kg/d (Q1, Q3: 50, 125). Among responders, 84.4% achieved cessation of ES within two weeks of initiation of therapy. 12.5% of children had a relapse over a 12-wk follow-up. Thirteen percent of children had adverse events, drowsiness being the most common (9.3%). The present study demonstrated modest short-term clinical effectiveness and tolerability of vigabatrin therapy in children with hormonal-therapy-resistant IESS.